Back

Estimating treatment effect of tafamidis on hospitalisation in NYHA class III ATTR-CM patients in the presence of death using principal stratification

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Chronic heart failure e-posters Epidemiology, Prognosis, Outcome ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor Huihua Li

Pfizer Inc., New York (United States of America)

218 More presentations in this session

Presentation thumbnail
Intermittent therapy with levosimendan in patients with advanced heart failure
Professor M. Weis (Munich, DE)
Abstract Slides
Presentation thumbnail
Differences in long-term all-cause and cardiovascular mortality according to heart failure aetiology in ambulatory patients
Doctor G. Spitaleri (Sant Joan Despi (Barcelona), ES)
Abstract Slides
Presentation thumbnail
Comparing the central arterial stiffness indices in the decompensated and compensated states of heart failure: a cohort study
Assistant Professor G. Youssef (Cairo, EG)
Abstract Slides
Presentation thumbnail
Opportunities for clinician education in the pharmacotherapy of stable heart failure
Doctor P. Murray (Toronto, CA)
Abstract Slides
Presentation thumbnail
Systolic blood pressure visit-to-visit variability and clinical outcomes of heart failure with preserved ejection fraction
Doctor Q. Zhang (Tianjin, CN)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure e-posters

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources